Compare ARL & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARL | LYEL |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.7M | 320.1M |
| IPO Year | 1999 | 2021 |
| Metric | ARL | LYEL |
|---|---|---|
| Price | $16.07 | $10.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.60 |
| AVG Volume (30 Days) | 1.9K | ★ 98.2K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 206.59 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,014,000.00 | $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8,712.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.70 | N/A |
| 52 Week Low | $12.42 | $11.47 |
| 52 Week High | $24.44 | $45.00 |
| Indicator | ARL | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 54.90 | 28.91 |
| Support Level | $15.65 | N/A |
| Resistance Level | $16.83 | $15.38 |
| Average True Range (ATR) | 0.39 | 0.84 |
| MACD | 0.12 | -0.44 |
| Stochastic Oscillator | 55.61 | 7.41 |
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.